The Oral GLP-1 Cage Match: Orforglipron vs Rybelsus
Eli Lilly’s once-daily oral GLP-1, orforglipron, outperformed Novo Nordisk’s oral semaglutide (Rybelsus) in a head-to-head diabetes study, reinforcing Lilly’s bid to lead in pills as well as injectables; the result extends the company’s incretin edge beyond Mounjaro/Zepbound and signals fiercer competition for oral market share as capacity and adherence dynamics shift toward convenient formulations.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-07-05
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Novo Nordisk Faces a Compliance Test
-
India’s API Trade Balance Turns Positive
-
BioNTech’s Founders Turn the Page
-
FDA Fee Updates Raise the Cost of Entering the U.S. Generic Drug Chain
-
API Supplier Audits Move to the Center of Pharma Supply Resilience
-
Rising API Costs Threaten Drug Prices
-
Lilly Bets Bigger on China
-
EFSA Reaffirms Safety of E948 Oxygen and E949 Hydrogen in All Foods No Health Risks Detected
-
EFSA Confirms Safety of Vitamin E TPGS as Food Additive New Opinion Covers Multiple Use Levels
-
Indian Pharma Urges US to Exempt Generics as 50 Percent Tariffs Loom National Security Probe Sparks Supply Fears
Recommend Reading
-
Platinum Chemotherapy Shortages Expose the Fragility of Essential API Supply
-
Lilly’s U.S. API Investment Highlights a New Phase of Pharma Supply Localization
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
FDA Names Veteran Oncology Regulator Pazdur as Director of Drug Review Center
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
Juhua’s Net Profit Soars Up to 155% with H1 Earnings Hitting 2.13 Billion Yuan as Refrigerants Surge 61.88%
-
ACME Solar Orders Over 3.1GWh Battery Storage in India’s Largest Deal to Power Multi-State FDRE Rollout
-
Indonesia Secures $10 Billion with ACWA Power for Renewables and Hydrogen Mega-Projects
-
Over 10,000 Aircraft Parts Targeted as Global Leaders Launch TPC Recycling Program for Airbus A380
-
China's Acetone Market Reverses Decline and Rises